Cancer Treatment Today

Fulvestrant is FDA indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. (Faslodex)Fulvestrant is a hormonal treatment that works differently than other hormonal treatments. It acts not by competing with estrogen but by selectively down modulating it and causing it to be degraded and disappear.   It used to be thought that this unique

Brand-name Aromasin is manufactured by Pfizer, Inc. However, the patent for this medicine has expired in early 2012, and it is now available in generic form. Aromasin is available in generic form in one strength: exemestane 25 mg tablets. Generic Aromasin is made by Roxane Laboratories, Inc., and Greenstone LLC. The version made by Greenstone is an "authorized generic," which means that it is actually made by Pfizer and is actually the real, brand-name

Is there a way to make cancers that stop responding to hormones increase their sensitivity to these drugs? Preclinical evidence suggests Herceptin (trustusumab) can restore and amplify responsiveness to hormonal therapy. The combination of Tykerb, which like Herceptin works on the HER receptor, and Femara is FDA approved and is thought to work through this mechanism. A randomized phase III TAnDEM study investigated Trastuzumab plus Arimidex(anastrozole)

Tamoxifen has different effects on different tissues. Whereas it blocks estrogen in the breast, it has pro- estrogenic effects on bone and in the uterus. Working as an estrogen-like substance, it can cause dysfunctional uterine bleeding and endometrial thickening and very rarely, superficial, easily treatable, endometrial cancer and sarcoma. In a review of all NSABP breast cancer treatment trials, the rate of sarcoma in women treated with tamoxifen